HeartSciences annual cash and equivalents
2022
2023
2024
2025
2026
2026
HeartSciences Cash & Equivalents Growth & History (HSCS)
HeartSciences's cash and equivalents was $1.7M for fiscal 2026.
View full HeartSciences company overviewHeartSciences annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2026 · Jun 30 | 2026-06-30 | $1.7M | — | — |
| 2026 · Apr 30 | 2026-04-30 | $1.7M | $600,000 | +54.55% |
| 2025 | 2025-04-30 | $1.1M | −$4.7M | −81.06% |
| 2024 | 2024-04-30 | $5.8M | $4.1M | +249.76% |
| 2023 | 2023-04-30 | $1.7M | $742,207 | +80.83% |
| 2022 | 2022-04-30 | $918,260 | — | — |
HeartSciences quarterly cash and equivalents
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q4.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 · Jun 30 | 2026-06-30 | $1.7M | — | — |
| Q4 2026 · Apr 30 | 2026-04-30 | $1.7M | $600,000 | +54.55% |
| Q3 2026 | 2026-01-31 | $3.4M | $800,513 | +30.83% |
| Q2 2026 | 2025-10-31 | $2.0M | −$2.1M | −51.85% |
| Q1 2026 | 2025-07-31 | $2.8M | −$1.5M | −35.66% |
| Q4 2025 | 2025-04-30 | $1.1M | −$4.7M | −81.06% |
| Q3 2025 | 2025-01-31 | $2.6M | −$4.5M | −63.31% |
| Q2 2025 | 2024-10-31 | $4.1M | $4.0M | +3946.29% |
| Q1 2025 | 2024-07-31 | $4.3M | $3.8M | +653.89% |
| Q4 2024 | 2024-04-30 | $5.8M | $4.1M | +249.76% |
| Q3 2024 | 2024-01-31 | $7.1M | $5.1M | +266.48% |
| Q2 2024 | 2023-10-31 | $100,144 | −$3.0M | −96.74% |
| Q1 2024 | 2023-07-31 | $575,654 | −$3.7M | −86.53% |
| Q4 2023 | 2023-04-30 | $1.7M | $742,207 | +80.83% |
| Q3 2023 | 2023-01-31 | $1.9M | — | — |
| Q2 2023 | 2022-10-31 | $3.1M | — | — |
| Q1 2023 | 2022-07-31 | $4.3M | — | — |
| Q4 2022 | 2022-04-30 | $918,260 | — | — |
HeartSciences cash and equivalents trends
Between the periods ended 2022-04-30 and 2026-06-30, HeartSciences's cash and equivalents increased from $918,260 to $1.7M, a change of $738,554. The latest reported quarter, Q4 2026 · Jun 30, shows $1.7M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review HeartSciences source filings ↗